Daabacaadii ugu dambeysay ee Ururka Caafimaadka Adduunka ee Kala soocida unugyada jilicsan iyo burooyinka lafaha, oo la daabacay Abriil 2020, ayaa kala saarayasarcomassaddex qaybood oo kala ah: sburooyinka unugyada, burooyinka lafaha, iyo burooyinka lafaha iyo unugyada jilicsan ee leh unugyo wareegsan oo aan kala sooc lahayn(sida EWSR1-non-ETS fusion round sarcoma).
"Kansarka la illoobay"
Sarcoma waa nooc naadir ah oo ka mid ahkansarka dadka waaweyn, xisaabinta ku saabsan1%Dhammaan kansarrada dadka waaweyn, oo inta badan loo yaqaan "Kansarka la illoobay."Si kastaba ha ahaatee, waa xadku badan carruurta, xisaabinta agagaarka15% ilaa 20%dhammaan kansarrada carruurnimada.Waxay ku dhici kartaa meel kasta oo jirka ka mid ah, inta badanna gudahagacmaha ama lugaha(60%), oo ay ku xigtojir ama caloosha(30%), iyo ugu dambeyntiimadaxa ama qoorta(10%).
Sanadihii la soo dhaafay, dhacdooyinka burooyinka lafaha iyo jilicsan ayaa si tartiib tartiib ah u kordhayay.Burooyinka asaasiga ah ee halista ah waxay ku badan yihiin dhalinyarada iyo shakhsiyaadka da'da dhexe waxaana ka mid ah osteosarcoma, Ewing sarcoma, chondrosarcoma, histiocytoma fibrous malignant, iyo chordoma, iyo kuwo kale.Burooyinka malignantiga ah ee unugyada jilicsan waxaa ka mid ah sarcoma synovial, fibrosarcoma, liposarcoma, iyo rhabdomyosarcoma.Kala-baxyada lafaha ayaa ku badan dadka da'da dhexe iyo waayeelka, oo leh burooyinka asaasiga ah ee caadiga ah waa kansarka sambabada, kansarka naasaha, kansarka kelyaha, kansarka qanjirka 'prostate', iyo kansarka thyroid, iyo kuwo kale.
Ogaanshaha hore, daawaynta hore - Iftiiminta "burooyinka" qarsoon
Sababtoo ah heerka sare ee soo noqnoqoshada guud ee sarcomas, burooyin badan ayaa leh baaritaanno qalliin ka hor oo aan caddayn oo aan lahayn baaritaanno sawir oo faahfaahsan.Tani waxay badanaa keentaa in la ogaado inta lagu jiro qalliinka in buradu aysan ahayn mid sahlan sida lagu qiyaaso qalliinka ka hor, taasoo keenta dib-u-soo-bax aan dhammaystirnayn.Dib-u-soo-noqoshada qaliinka ka dib ama metastasis ayaa laga yaabaa inay dhacdo, taasoo keenaysa bukaanada inay seegaan fursada daaweynta ugu fiican.Sidaa darteed,ogaanshaha hore, ogaanshaha saxda ah, iyo daawaynta wakhtiga ku haboon ayaa saamayn wayn ku leh saadaasha bukaanka. Maanta, waxaan jeclaan lahayn inaan soo bandhigno khabiir la ixtiraamo oo leh ku dhawaad 20 sano oo waayo-aragnimo ahogaanshaha caadiga ah iyo daaweynta shakhsi ahaaneed ee sarcoma unugyada jilicsan, waxaana si weyn u ammaanay warshadaha iyo bukaannada labadaba -DhakhtarLiu Jiayongoo ka socda Waaxda Lafaha iyo Tissue Jilicsan ee Cisbitaalka Kansarka ee Jaamacadda Peking.
Soo Bandhigidda Khabiirka Aqoonta Qoto dheer ee Lafaha iyo Xanuunka Hilibka – Dr..Liu Jiayong
Dhakhtarka Daawada, Dhakhtarka Sare, Professor Associate.Waxa uu wax ku bartay Xarunta Kansarka ee Anderson ee dalka Maraykanka.
Khabiir:Daawaynta dhamaystiran ee sarcomas unugyada jilicsan (dib u soo celinta qaliinka iyo dib u dhiska, kiimoterabiga, daaweynta la beegsaday, iyo immunotherapy);daaweynta qalliinka melanoma.
Iyada oo ku dhawaad 20 sano oo waayo-aragnimo caafimaad ah, Doctor Liu Jiayong waxa uu ururiyay khibrad daawaynta bukaan-socod iyo qalliin oo ballaadhanogaanshaha caadiga ah iyo qorshooyinka daawaynta ee gaarka ahee sarcoma unugyada jilicsan ee caadiga ah sida sarcoma pleomorphic aan kala sooc lahayn, liposarcoma, leiomyosarcoma, sarcoma synovial, adenocystic carcinoma-sida sarcoma, epithelioid sarcoma, fibrosarcoma, angiosarcoma, iyo fibromatosis infiltrative.Isagu waa gaar ahaanku takhasusay maaraynta xididdada dhiigga iyo neerfayaasha inta lagu jiro dib-u-soo-celinta sarcoma addimada, iyo sidoo kale hagaajinta iyo dib-u-dhiska cilladaha unugyada jilicsan ee maqaarka.Dhakhtar Liu si samir leh ayuu u dhagaystaa bukaan kasta, si taxadir leh ayuu wax uga waydiiyaa taariikhdooda caafimaad, wuxuuna qaataa diiwaanno caafimaad oo taxadar leh.Waxa uu si gaar ah u eegayaa isbeddelada xaaladda bukaanka waqtiyo kala duwan, sida ka hor iyo ka dib qalliinka, inta lagu jiro daaweynta, dabagalka, iyo horumarka cudurka, samaynta go'aamo sax ah iyo hagaajinta wakhtiga qorshooyinka daaweynta.
Dhakhtarka Liu Jiayong wuxuu hadda u adeegaa xubin ka mid ah unugyada jilicsan ee Sarcoma iyo Kooxda Melanoma ee Ururka Kansarka Shiinaha ee Ka-hortagga Kansarka, iyo sidoo kale xubin ka mid ah Kooxda Burooyinka Lafaha ee Bulshada Beijing ee Orthopedics ee Ururka Caafimaadka Shiinaha.2010, wuxuu ahaa kii ugu horreeyay ee Shiinaha si uu u tarjumo oo u daabaco " Tilmaamaha Dhaqanka Clinical Clinical ee NCCN ee Sarcoma Tissue Soft ", kor u qaadida daaweynta dhamaystiran ee sarcomas unugyada jilicsan.Waxa uu sii wadaa inuu ku dadaalo horumarinta cilmi baarista kiliinikada iyo sayniska, inkastoo uu leeyahay culeys weyn oo bukaan ah.Wuxuu u heellan yahay oo mas'uul ka yahay bukaan kasta oo uu daweynayo, iyo inta lagu jiro cudurka faafa, wuxuu wax ka qabtay dhibaatooyinka ay la kulmaan bukaannada raadinaya daryeel caafimaad isagoo si degdeg ah uga jawaabay la-talinta bukaan-socodka, dib-u-eegista natiijooyinka daba-galka ah, iyo bixinta talooyinka daaweynta habboon ee la-talinta internetka sida Kooxda Bukaanka ee Dhakhtarka Wacan.
Kiiskii u dambeeyay
Mr. Zhang, oo ah bukaan 35 jir ah, ayaa si lama filaan ah ula kulmay luminta aragga horraantii 2019. Ka dib, waxaa lagu sameeyay qalliin indho-indhayn ah oo isha bidix ah sababtoo ah korodhka joogtada ah ee cadaadiska indhaha.Baadhitaanka qalliinka ka dib ayaa shaaca ka qaaday pseudotumor barar ah.Xagaagii isla sanadkaas, qanjidhada sambabada oo badan ayaa la helay intii lagu jiray baadhis dabagal ah, laakiin ma jiro unugyo buro ah oo laga helay ka-qaadista irbado.Baaritaano dheeraad ah oo dabagal ah ayaa muujiyay metastassyo badan oo lafo iyo sambabada ah.La-talintii isbitaallada maxalliga ah iyo kuwa heer-sare waxay ku sheegeen inuu qabo buro-bararka myofibroblastic barar ah.Bishii Agoosto 2022, waxa uu maray kiimoterabi heersare ah, kaas oo si weyn uga nafisiyay xanuunkiisa laakiin ma muujin wax horumar ah oo muuqda oo nabarada ah markii dib loo qiimeeyo.Xaaladiisa jireed ayaa sidoo kale daciiftay.Iyadoo ay taasi jirto, qoyskiisu marnaba ma rajo dhigin.Ka dib markii ay raadiyeen fikrado badan, waxay u yimaadeen dareenka dhakhtarka Liu Jiayong bishii Nofembar 2022. Ka dib markii ay si taxadar leh dib u eegis ku sameeyeen taariikhda caafimaadka bukaanka, dhammaan diiwaanada caafimaadka, baaritaanada cudurada, iyo xogta sawirka,DhakhtarLiu waxa uu soo jeediyay daawayn kiimoterabi oo ka kooban methotrexate-yar iyo Changchun Ruibin.Habkan kiimoteraabiga ah waa mid kharash-ool ah wuxuuna leeyahay waxyeellooyin yar.Ka dib 35 maalmood oo daawo ah, CT-ga oo dabagal ah ayaa muujisay in cufnaanta sambabada midig ay meesha ka baxday, taas oo muujinaysa xakamaynta wanaagsan ee burada.Baadhitaan dabagal ah oo dhawaan lagu sameeyay Cusbitaalka Oncology ee Gobolka Koonfurta ee Beijing ayaa muujisay xaalada sambabada oo degan, dhakhtar Liu waxa uu ku taliyay booqashooyin joogto ah.Bukaanka iyo qoyskiisu hadda waxay kalsooni weyn ku qabaan daawaynta xigta, oo ay ka buuxdo rajo.Waxa ay dareemeen in ay soo arkeen ifin iftiimaya safarka daawaynta waxa ayna si kal iyo laab ah ugu mahad naqeen iyaga oo soo bandhigay calan xariir ah oo mahadnaq ah.
Waqtiga boostada: Agoosto-25-2023